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Novel approaches for the qualitative and quantitative pro-
teomics analysis by nanoscale LC-MS applied to the study
of protein expression response in depleted and unde-
pleted serum of Gaucher patients undergoing enzyme
replacement therapy are presented. Particular emphasis
is given to the method reproducibility of these LC-MS
experiments without the use of isotopic labels. The level
of chitotriosidase, an established Gaucher biomarker,
was assessed by means of an absolute concentration
determination technique for alternate scanning LC-MS
generated data. Disease associated proteins, including
fibrinogens, complement cascade proteins, and members
of the high density lipoprotein serum content, were recog-
nized by various clustering methods and sorting and inten-
sity profile grouping of identified peptides. Condition-
unique LC-MS protein signatures could be generated
utilizing the measured serum protein concentrations and
are presented for all investigated conditions. The clustering
results of the study were also used as input for gene ontol-
ogy searches to determine the correlation between the mo-
lecular functions of the identified peptides and proteins.
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The most frequently encountered inherent lysosomal stor-
age disorder in man is glycosylceramidosis, better known as
Gaucher disease. The disorder is caused by an inherited
deficiency in glucocerebrosidase, the enzyme catalyzing the
degradation of glucosylceramide to ceramide and glucose.
Lipid accumulation is restricted to tissue macrophages, so-
called Gaucher cells, that act as the starting point of patho-
physiological processes resulting in clinical symptoms. The
clinical presentation of Gaucher disease is heterogeneous
with respect to age, nature, and progression of symptoms (1).
Clinical manifestation is accompanied by abnormalities in se-
rum composition. The most striking abnormality is a thou-
sandfold elevated serum level of chitotriosidase, a protein
massively expressed and secreted by the pathological Gau-
cher cells (2). Although chitotriosidase is an excellent biomar-
ker, a major drawback is the frequent genetic deficiency in
this enzyme among Caucasians with approximately one in
every 20 individuals not expressing any chitotriosidase (3).
This limitation has prompted a search for further Gaucher cell
biomarkers. The availability of biomarkers for Gaucher dis-
ease is of particular importance because the availability of
effective therapeutic interventions based on supplementation
with recombinant glucocerebrosidase (4) or pharmacological
reduction of glycosphingolipid biosynthesis (5) is costly. The
monitoring of chitotriosidase as a biomarker of Gaucher dis-
ease is generally applied in a clinical setting for both therapy
initiation and optimization of individual dose regimes (6).
Given the limitations concerning chitotriosidase, identification
and quantification of additional biomarkers for Gaucher dis-
ease is therefore of great value (7).
2D1 gel-based separation methods combined with mass
spectrometry have been the standard for the separation, iden-
tification, and quantification of proteins. The method has to
date the greatest potential to separate complex protein mix-
tures comprising up to thousands of components. It also has
limitations with regard to the separation of certain protein
classes and quantification in general. The quantitative limita-
tions have been detailed elsewhere (8, 9), but they primarily
arise from ambiguity in the identification of multiple proteins
present in a single spot, identification of proteins at both
extremes of the pI range, small proteins, variants and modi-
fications, in-gel degradation, and variation in extraction effi-
ciency. As a complementary alternative, LC-MS-based rela-
tive quantification methods have emerged to identify and
quantify peptides and proteins in mixtures of various com-
plexities. The majority of these relative quantification tech-
niques use the introduction of stable isotopes into the sam-
ples including ICAT (10), isobaric tag for relative and absolute
quantification (iTRAQ) (11), in vivo stable isotope labeling by
amino acids in cell culture (SILAC) (12), and 18O labeling (13,
14). They typically require multiple sample preparation steps
that could result in an increase in experiment variability and a
decrease in accuracy. Recent articles have reviewed stable
isotope labeling approaches and contrasted their advantages
and limitations with quantitative differential in-gel electro-
phoresis methods (15–17).
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More recently, label-free LC-MS quantification methods
have been described to determine relative abundances of
proteins between multiple conditions (18–24). These methods
are typically based on determining peak area ratios of the
same peptides between different conditions. The quantitative
reproducibility of these methods depends upon the peptide
cluster efficiency, which is determined by the mass measure-
ment accuracy and precision and the chromatographic reten-
tion time reproducibility obtained during the experiment. A
recent independent study from the Association of Biomolecu-
lar Resource Facilities evaluated quantitative proteomics ap-
proaches, and it was concluded that label-free methods did at
least as well as stable isotope labeling methods.2 Moreover
Silva et al. (25) discovered that a label-free approach allows
for the estimation of absolute protein concentrations, which
were subsequently used for stoichiometry studies.
In this study, a gel-free and label-free LC-MS approach is
presented to conduct qualitative and quantitative serum anal-
ysis. The Gaucher disease protein serum profile was exam-
ined as it is biochemically and quantitatively well defined. The
identification and enzyme activity determination of a known
Gaucher disease biomarker will be demonstrated and cross-
validated with its biochemical known activity. Furthermore
clustering methods are described to evaluate the data quality
of quantitative label-free LC-MS data sets. Clustering was
also used for trend identifications based on absolute deter-
mined concentrations. Intensity profiling by K-means cluster-
ing of identified peptides was used to identify interrelating
proteins, for example proteins that are components of the
same biochemical pathway.
EXPERIMENTAL PROCEDURES
Sample Group—The control and patient samples studied were
known either by contact with the Netherlands Gaucher Society or by
referral to the Academic Medical Center. The diagnosis of Gaucher
disease was based on deficient glucocerebrosidase activity in leuko-
cytes and/or urine samples. EDTA plasma samples were obtained
from freshly drawn blood and immediately stored at 20 °C. Serum
samples from the patients were obtained prior to treatment by means
of enzyme replacement therapy and after 6.5 years of treatment.
Chitotriosidase activity was measured as described previously (2).
Sample Preparation/Protein Depletion—Serum samples from the
control, the patient pretreatment, and the patient post-treatment were
either digested as received or passed through a 10-cm  4.6-mm
multiaffinity removal system column (Agilent Technologies, Palo Alto,
CA) to deplete the samples. Hence targeted high abundance proteins,
including albumin, IgG, antitrypsin, IgA, transferrin, and haptoglobin,
were removed.
10 l of the undepleted serum samples was diluted with 50 mM
ammonium bicarbonate (Sigma-Aldrich) prior to enzymatic digestion.
A 20-l aliquot of the serum samples was used for depletion with the
multiaffinity removal system according to the manufacturer’s proto-
col. The mobile phase buffers were provided with the system and
used as received. Briefly 20 l of serum were diluted 5-fold with 80 l
of buffer A, and particulates were removed by centrifugation through
a 0.22-m spin filter (Millipore, Billerica, MA) at 13,000 rpm for 3 min.
The proteins were separated with a step gradient; the first 10 min of
the gradient were maintained at 100% mobile phase A at 0.5 ml/min
followed by a step to 100% mobile phase B with a flow rate of 1.0
ml/min in 0.1 min where the composition was maintained for 7 min.
Reconditioning of the column was conducted with mobile phase A
buffer at 1.0 ml/min for 11 min. The depletion efficiency was esti-
mated to be 50% based on UV absorption peak area ratio of the
break-through and bound fraction. The flow-through fractions were
collected and buffer-exchanged with 50 mM ammonium bicarbonate,
and the volume was reduced to 80 l.
Protein Digestion Protocols—10 l of undepleted serum was di-
luted with 65 l of 50 mM ammonium bicarbonate solution and de-
natured in the presence of 10 l of 1% RapiGest detergent solution
(Waters Corp., Milford, MA) at 80 °C for 15 min (26). The serum
samples were reduced in the presence of 5 l of 100 mM dithiothreitol
(Sigma-Aldrich) at 60 °C for 30 min. The proteins were alkylated in the
dark in the presence of 5 l of 200 mM iodoacetamide (Sigma-Aldrich)
at ambient temperature for 30 min. Proteolytic digestion was initiated
by adding 15 l of 0.5 g/l sequencing grade, modified trypsin
(Promega, Madison WI) and incubated overnight at 37 °C. Breakdown
of the acid-labile detergent was achieved in the presence of 4 l of an
aqueous 12 M HCl solution at 37 °C for 15 min. The tryptic peptide
solutions were centrifuged at 13,000 rpm for 10 min, and the super-
natant was collected. The enzymatic digestion and treatment of the
depleted serum solutions was as described above with the exception
of the addition of 20 l of 0.5 g/l trypsin solution.
Prior to analyses, the tryptic peptide solutions were 10-fold diluted
with an aqueous 0.1% formic acid (Sigma-Aldrich) solution. A protein
digest internal standard was added (1:1 dilution with 100 fmol/l
enolase from Saccharomyces cerevisiae) to perform absolute quan-
tification. The LC-MS analyses were performed using 2 l of the final
serum protein digest mixtures.
Recombinant chitotriosidase (Genzyme, Cambridge, MA) was di-
gested as described above with minor modification. 87 l of a 50 mM
ammonium bicarbonate solution was added to 5 l of 1 mg/ml chi-
totriosidase stock solution. The recombinant chitotriosidase was re-
duced in the presence of 1 l of 100 mM dithiothreitol at 60 °C for 30
min. Alkylation was conducted in the dark for 30 min by adding 2 l
of 100 mM iodoacetamide. Digestion was initiated by adding 5 l of
0.5 g/l modified sequencing grade trypsin and incubated overnight
at 37 °C.
LC-MS Configuration—Nanoscale LC separation of tryptic pep-
tides was performed with a NanoAcquity system (Waters Corp., Mil-
ford, MA) equipped with a Symmetry C18 5 m, 5-mm  300-m
precolumn and an Atlantis C18 3 m, 15-cm  75-m analytical
reversed phase column (Waters Corp.). The samples were initially
transferred with an aqueous 0.1% formic acid solution to the precol-
umn with a flow rate of 4 l/min for 3 min. Mobile phase A was water
with 0.1% formic acid, and mobile phase B was 0.1% formic acid in
acetonitrile. The peptides were separated with a gradient of 3–40%
mobile phase B over 90 min at a flow rate of 300 nl/min followed by
a 10-min rinse with 90% of mobile phase B. The column was re-
equilibrated at initial conditions for 20 min. The column temperature
was maintained at 35 °C. The lock mass was delivered from the
auxiliary pump of the NanoAcquity pump with a constant flow rate of
200 nl/min at a concentration of 100 fmol of [Glu1]fibrinopeptide B/l
to the reference sprayer of the NanoLockSpray source of the mass
spectrometer. All samples were analyzed in triplicate.
Analysis of tryptic peptides was performed using a Q-Tof Premier
mass spectrometer (Waters Corp., Manchester, UK). For all measure-
ments, the mass spectrometer was operated in the v-mode of anal-
2 A. M. Falick, J. A. Kowalak, W. Lane, K. Lilley, B. Phinney, C.
Turck, S. Weintraub, E. Witkowska, and N. Yates, The Proteomics
Research Group 2006 Quantitative Proteomics Study, Association of
Biomolecular Resource Facilities, unpublished data.
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ysis with a typical resolving power of at least 10,000 full-width
half-maximum. All analyses were performed using positive nanoelec-
trospray ion mode. The time-of-flight analyzer of the mass spectrom-
eter was externally calibrated with NaI from m/z 50 to 1990 with the
data post acquisition lock mass corrected using the monoisotopic
mass of the doubly charged precursor of [Glu1]fibrinopeptide B. The
reference sprayer was sampled with a frequency of 30 s. Accurate
mass LC-MS data were collected in an alternating low energy and
elevated energy mode of acquisition (27, 28). The spectral acquisition
time in each mode was 1.5 s with a 0.1-s interscan delay. In low
energy MS mode, data were collected at a constant collision energy
of 4 eV. In elevated energy MS mode, the collision energy was
ramped from 15 to 40 eV during each 1.5-s data collection cycle with
one complete cycle of low and elevated energy data acquired every
3.2 s. The radio frequency applied to the quadrupole mass analyzer
was adjusted such that ions from m/z 300 to 2000 were efficiently
transmitted, ensuring that any ions less than m/z 300 observed in the
LC-MS data only arose from dissociations in the collision cell.
Data Processing and Protein Identification—Continuum LC-MS
data were processed and searched using ProteinLynx GlobalServer
version 2.2.5 (Waters Corp.). Protein identifications were obtained
with the embedded ion accounting algorithm of the software and
searching a human database to which data from S. cerevisiae enolase
were appended. The ion detection, clustering, and normalization were
performed using ProteinLynx GlobalServer. The principles of the ap-
plied data clustering and normalization have been explained in great
detail in previous publications (18, 20). Intensity measurements are
typically adjusted on those components, i.e. deisotoped and charge
state-reduced accurate mass retention time pairs, that replicate
throughout the complete experiment for analysis at the accurate
mass/retention cluster level. Components are typically clustered to-
gether with a 10 ppm mass precision and a 0.25-min time toler-
ance. Alignment of elevated energy ions with low energy precursor
peptide ions is conducted with an approximate precision of 0.05
min. For analysis on the protein identification and quantification level
the observed intensity measurements are normalized on the intensity
measurement of the identified peptides of the digested internal
standard.
The underlying principles of the ion accounting search algorithm
have been recently described by Li et al.3 In brief, all fragment ions
within a retention time window associated to 1⁄10 of the chromato-
graphic peak width of a precursor ion are time-aligned or assigned to
the precursor. The resulting precursor-product ion list is then queried
against a database utilizing an iterative three-step process whereby
the culmination of each loop increases the selectivity and sensitivity
of the next. In addition, the method utilizes limited database queries
whereby each query accesses different sets and subsets of peptides
from the proteins present in the database.
During the first step, the data are matched to only correctly cleaved
proteolytic peptides whose precursor and product ion mass toler-
ances are within the specified tolerances, typically 10 ppm for pre-
cursor ions and 20 ppm for product ions. As a consequence of these
database search tolerances, each submitted precursor provides mul-
tiple tentative peptide identifications. However, the overall strategy of
the search algorithm requires that only one peptide identification is
provided for each detected precursor. As a result, all other low
ranking tentative peptide identifications to each securely identified
precursor are not considered. In addition, the product ions used for
the validation of each high ranking precursor are removed from the
precursor-product list of other co-eluting precursors, thereby elimi-
nating them for consideration when identifying coincidentally de-
tected precursors. During the second step, precursor and product
ions that have not yet been assigned are queried against a subset
database of the identified proteins from the first step. This includes
missed cleavages, in-source fragments, neutral losses, and variable
modifications. During the last step, the remaining unidentified ions are
considered against the complete database for additional protein iden-
tifications, including peptide mass fingerprint identifications.
The protein identifications were based on the detection of more
than two fragment ions per peptide, more then two peptides meas-
ured per protein, and identification of the protein in at least two of
three injections. The false positive rate of the ion accounting identi-
fication algorithm is typically 3–4% with a randomized database 5
times the size of the original utilized database. However, by using
replication as a filter, the false positive rate is minimized as false
positive identifications have a random nature and as such do not tend
to replicate across injections. Additional data analysis was performed
with Decisionsite (Spotfire, Somerville, MA), Excel (Microsoft Corp.,
Redmond, WA), and Simca-P (Umetrics, Umeå, Sweden).
RESULTS
Data Quality Evaluation—The observed intensity measure-
ments were normalized for injection volume and protein load
variability before conducting quantitative comparisons be-
tween conditions by applying scaling as outlined under “Ex-
perimental Procedures” and in previously published studies
(18, 20). A binary comparison of the peptide precursor inten-
sity measurements of two injections of one of the investigated
conditions is discussed. A 45° diagonal line is obtained (Fig. 1)
with almost no variation throughout the detected range. In-
tersection through the origin would have been obtained if not
for the scatter on measurements for low intensity ions, i.e. no
or minimal deviation between matched components. This ex-
ample demonstrates the expected distribution in the instance
of no obvious change between the investigated injections or
conditions. The number of detected accurate mass/retention
time pairs identified in both injections was 9292 and 9145 of
which 8364 were found to be common to both injections. The
number of non-redundant identified peptides from these two
particular injections, utilizing the high energy fragmentation
spectra and the search criteria described under “Experimental
Procedures,” were 1705 (18.3%) and 1725 (18.9%), respec-
tively. This search considered normal tryptic cleavage rules
with only one missed tryptic cleavage site allowed and was
limited to consider only a single modification, carbamidom-
ethylation of cysteine residues. The summed precursor inten-
sities of these non-redundant identifications for the two injec-
tions mentioned correspond to 45.3 and 50.7% of the total ion
intensity (amount) that can be detected. These fraction num-
bers can be considered adequate for depleted sera and are
comparable with those reported previously for microbial sys-
tems (19).
These types of quality control measurements were per-
formed on all injections and conditions. For the depleted
samples, comprising three conditions/nine injections, the
3 Li, G.-Z., Golick, D., Gorenstein, M. V., Silva, J. C., Vissers,
J. P. C., and Geromanos, S. J. (2006) A novel ion accounting algo-
rithm for protein database searches, Poster W079 presented at the
Human Proteome Organisation (HUPO) 5th Annual World Congress,
Long Beach, CA (October 28–November 1, 2006).
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measured median and average mass precision were 1.90 and
2.52 ppm, respectively. The median and average retention
time errors were 0.80 and 0.91%. This emphasizes the re-
quired stability of intensity, mass measurement, and retention
time for label-free quantitative LC-MS measurements. These
observations are within the typical error measurements re-
ported in a previous study (18) where also more detail is given
on accurate mass and retention time clustering, data normal-
ization/scaling, and quantification.
Relative Quantification—Prior to conducting quantitative
comparisons between conditions, the observed intensity
measurements were normalized on the intensity measure-
ment of the internal standard peptides. In contrast to the
normalization method mentioned above, this method utilizes
the three most abundant peptides identified to a protein for
normalization (25). In those instances where the protein iden-
tification was based on two peptides, normalization was con-
ducted with the two best ionizing peptides. Details on protein
identification are described under “Experimental Procedures.”
The relative standard deviation on the summed intensity
measurement of the three most abundant peptides identified
to a protein for all identified proteins for the six investigated
conditions was found to be equal to 13.6% (see Supplemental
Table 1; statistical outliners not excluded), which agrees well
with earlier reported values using label-free quantification
techniques (18, 20, 24, 29, 30). The significance of regulation
level was specified at 30%. Hence 1.3-fold (0.30 natural log
scale) was used as a threshold to identify significant up- or
down-regulation, which is typically 2–3 times the estimated
error on the intensity measurement. The provision for a pre-
cursor ion to be included for a qualitative measurement was
identification based on the search criteria described under
“Experimental Procedures.” Hence an assured precursor in-
tensity threshold, typically 250 counts per acquisition scan,
had to be reached to generate fragment ions of sufficient
intensity for identification. In total, 108 non-redundant pro-
teins were identified in the complete sample set of which 46
proteins were common to depleted and undepleted serum. 20
proteins were uniquely identified in the undepleted samples. A
further 42 unique proteins were identified in the depleted
serum samples.
The relative ratios and variation were individually calculated
for each protein from the absolute quantification results cal-
culated within the undepleted and depleted data sets (see
Supplemental Table 2, a and b). These were calculated using
the normalized summed ion intensity as described above and
expressed as relative values. Of the 66 proteins identified in
the undepleted sera, 35 were found to be common across all
conditions, control, pretreatment, and post-treatment. For the
88 proteins identified in the depleted sera the cross-section of
the three conditions equaled 56 proteins. Both cross-sections
were analyzed independently, and the relative summed inten-
sity ratio of the pre- and post-treatment samples versus the
control samples was expressed. The majority (50 of 56) of the
commonly identified proteins in the depleted identification
cross-section show a clear trend to normalize as a result of
FIG. 1. elog intensity accurate mass/
retention time clusters for injection 1
versus elog intensity accurate mass/
retention time clusters for injection 2
of one of the investigated conditions
(depleted pretreatment serum).
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treatment (Fig. 2). A few proteins even show some overshoot.
Similar results were obtained for the undepleted cross-sec-
tion data set. In this instance, 29 of 35 proteins exhibited a
similar trend upon treatment.
In addition to the relative amounts, estimated absolute se-
rum protein concentrations are provided for the investigated
undepleted control sample (see supplementary Table 2c) as
these results are not affected/biased due to any sample han-
dling or affinity depletion. The results of a more comprehen-
sive evaluation with regard to estimating absolute protein
serum concentrations by means of LC-MS are presented
elsewhere (25). The lower limit of quantification, based upon
protein identification, was found to be 2.7 orders lower
compared with the most abundant protein present in serum.
This again required that the peptide had to be identified as
described in the previous paragraphs; this is independently
applicable to both depleted and undepleted serum. The esti-
mated limit of detection at the peptide level, assuming that the
precursor retention time and accurate mass are known, is
3.5 orders lower compared with the highest abundant iden-
tified peptides; this approaches the linear dynamic range of
the analytical technique used in this work.
Chitotriosidase Enzyme Activity—Recently published quan-
tification rules (25) were used to calculate the amount and
enzyme activity of chitotriosidase, a known biomarker for
symptomatic Gaucher disease patients. Monitoring the con-
centration of chitotriosidase and other regulated proteins dur-
ing treatment by means of LC-MS could be a measure for
treatment efficacy. The absolute quantification method relies
on the fact that the average MS signal response for the three
most intense tryptic peptides per mole of protein is a con-
stant. Given a reference, a digest of enolase from S. cerevisiae
in this case, this relationship is used to calculate an instru-
ment response factor for each analysis.
With this method, the average concentration of the three
injections of chitotriosidase in the pretreatment sample was
equal to 1.59  0.31 fmol/l, which can be calculated back to
an actual enzyme activity of 39,500  7860 nmol/mlh. The
determined amino acid sequence coverage for chitotriosidase
was 29.2%. The enzyme activity for chitotriosidase was also
determined with 4-methylumbelliferyl -D-N,N,N	-triace-
tylchitotriose substrate assay (31) and found to be equal to
31,800 nmol/mlh  5%. The chitotriosidase level measured
with both methods is in the same order of magnitude and
varies by only 20%. The advantage of the LC-MS approach is
the ability to calculate absolute concentrations of multiple
proteins simultaneously without the requirement for isotope-
labeled internal standards. It was necessary to deplete the
FIG. 2. Relative protein quantification results for the identification intersection of the depleted serum samples, i.e. pretreatment
versus control and post-treatment versus control (see Supplemental Table 2b for a complete overview of the identified and quantified
proteins). Relative pretreatment/control quantities (gray bars) and relative post-treatment/control quantities (red bars) are shown.
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patient serum to address the serum sample dynamic range to
identify and quantify chitotriosidase in the pretreatment sam-
ple. The applied methods described in this and the following
sections, however, can be equally successfully applied to
undepleted samples.
Three additional samples obtained from other type 1 Gau-
cher disease patients were analyzed to statistically validate
the levels and determined concentration from the LC-MS data
discussed in the previous paragraph. The results of these
experiments are summarized in Table I and are in agreement
with the above mentioned observations that chitotriosidase is
significantly elevated in the serum of patients suffering from
type I Gaucher disease.
LC-MS Protein Signatures—Most protein signatures are
based on comparative studies involving 2D gel separation of
the proteins in their intact form and subsequent identification
by means of MALDI-TOF-MS or LC-MS/MS (15, 16). The
signatures with the 2D gel approach are derived from gel
image analyses, identifying protein groups that share a motif
or exhibit common change, and are typically presented in
table format. Further analysis is sometimes performed by
means of principal component analysis (PCA), or hierarchical
clustering of the data, based on protein identification and their
associated regulation. Gene and protein microarrays are more
common tools to visualize condition-specific signatures,
which allow subsequent searching of the profile against as-
sembled collections of microarrays to identify, or classify,
disease.
The absolute protein concentration values allow for the
generation of so-called condition-specific signatures based
on label-free quantitative LC-MS data sets, which were re-
cently introduced for a breast cancer study.4 Briefly a refer-
ence protein is identified within the condition that is present at
a given level. Alternatively the exogenous protein spike can be
used. Note that this does not necessarily have to be the same
protein in every condition as the protein concentration signa-
ture will not be relative to another condition but simply relative
to a constant amount. Hence it is not important that the
protein identity is identical as long as the amount is. The
absolute protein amounts for all other identified proteins in a
condition are expressed versus the absolute protein amount
of the reference (Fig. 3). A number of proteins, undergoing
significant change, are color-annotated to illustrate the signa-
ture usefulness. For instance, apolipoprotein A-I and comple-
ment C3 are at a relatively high concentration in the control, at
a relatively low concentration when treatment is started, and
subsequently close to the control concentration level again in
the post-treatment sample. By annotating selected proteins,
disease types can be characterized in a global manner by
looking at a specific panel of proteins within the plasma
proteome as a whole. In this example, apolipoprotein A-I,
apolipoprotein C-II, complement C3, and chitotriosidase are
proteins that have been shown previously to be regulated in
Gaucher patients (4, 6, 32). To date, signatures have been
determined for the pre- and post-treatment patient samples
and a single control. Midtreatment signatures are currently
considered as a treatment monitor tool. A more extensive
study with a larger patient group is currently ongoing to clin-
ically validate the identified serum signatures.
Data Clustering: Multivariate Analysis—The data can be
clustered in various ways to identify the quality of the data set,
to identify differences between conditions, and to generate
profiles. PCA can be conducted on the peptide mass/reten-
tion time cluster or the protein identification/protein concen-
tration (amount) level. Prior to PCA on the peptide mass/
retention time cluster level, normalization of the data set was
conducted by normalizing on the total ion intensity for every
injection as described under “Experimental Procedures.”
From the results (Fig. 4a) it can be concluded that the replicate
injections for each condition are consistent as they cluster
closely together. In other words, PCA allows for the rapid
verification of the quality of the conducted experiment. Fur-
thermore it can be seen that the PCA experiment separated
the three investigated conditions, control, patient pre-, and
post-treatment. Hence the enzyme replacement therapy had
a clear effect shown by the separation of the pre- and post-
treatment injections. However, PCA by itself at the peptide
mass/retention time cluster level is not conclusive in deter-
4 Vissers, J. P. C., Kipping, M., Reimer, T., Kasten, A., Koy, C.,
Langridge, J. I., and Glocker, M. O. (2006) Quantification of diagnostic
protein signatures of polygenic diseases characterized by mass spec-
trometric proteome analysis: a study on mamma carcinoma, Poster
168 presented at the 2006 Meeting of the Association of Biomolecular
Resource Facilities, Long Beach, CA (February 11–14, 2006).
TABLE I
Measured concentration and activity of chitotriosidase of four
pretreatment type 1 Gaucher disease patients









Ad 1.59  0.31 39,500  7,860 31,800  1,590
Be 0.99  0.16 27,600  4,370 15,900  800
Ce 1.59  0.18 44,600  4,950 62,100  3,100
De 1.01  0.05 28,400  1,400 20,400  1,020
a Chitotriosidase concentration determined by means of LC-MS
(see 	Experimental Procedures	 for details).
b Chitotriosidase activity derived from LC-MS concentration meas-
urements.
c Chitotriosidase activity accessed by means of 4-methylumbel-
liferyl -D-N,N,N	-triacetylchitotriose substrate assay (see Ref. 31 for
method details).
d Sample preparation and depletion as described under 	Experi-
mental Procedures.	
e As in Table I, Footnote d but with minor modification in terms of
the affinity column batch material, dilutions, and injection volumes.
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mining treatment efficiency as the number of dimensions was
not significantly reduced. Therefore this type of analysis can
be regarded as a first pass control for an experiment as outlier
injections are easily identified and condition similarities/differ-
ences can easily be detected.
The protein identification results for the depleted and un-
depleted serum samples were annotated with absolute deter-
mined concentrations for PCA at the protein identification
level (Fig. 4b). However, PCA can be easily skewed by the
presence of unique proteins such as the targeted depleted set
of proteins in the case of a comparison between the depleted
and undepleted serum samples. Therefore, only the proteins
that were identified in all injections within all conditions were
taken into consideration for PCA. The two main principle
components can be easily identified as treatment and deple-
tion (Fig. 4b). The latter is a result of unspecific partial binding
of non-targeted proteins or additional sample handling losses.
For instance, the absolute estimated concentrations of apo-
lipoprotein C-III and vitronectin for the non-depleted control
sample, based upon three consecutive injections and identi-
fications, were 9.85107 and 2.24108 pg/ml; the reported
literature values are, respectively, 10.00107 and 2.60108
pg/ml (33). This agreement between LC-MS and biochemical
quantification methods has been studied across a larger pa-
tient population (25), and good correlation was observed be-
tween techniques for 11 well characterized serum proteins.
The absolute concentration values of apolipoprotein C-III and
vitronectin in the depleted control sample were 1.55107 and
0.86108 pg/ml indicating a non-specific loss of protein as a
result of sample handling. The average loss of protein as a
result of the applied depletion technique and additional sam-
ple handling was found to be 50%. However, no generic
depletion fractionation factor can be derived as this is de-
pendent on the interaction of these proteins with either the
affinity column or their interaction with the targeted proteins.
This is despite the fact that the applied depletion technique is
FIG. 3. Condition-independent absolute quantification depleted serum protein signatures: 2log ratio of the absolute protein con-
centration versus absolute internal standard concentration for the pretreatment serum sample (left), the post-treatment serum
sample (middle), and the control serum sample (right). Annotated proteins are: 1-acid glycoprotein (red), 2-antiplasmin (dark blue),
apolipoprotein A-I (yellow), apolipoprotein C-II (black), C4b-binding protein  chain (bright green), chitotriosidase (turquoise), complement C1q
subcomponent (light blue), complement C3 (pink), serum amyloid A-4 (gray-green), and vitronectin (brown-red).
Quantitative LC-MS Serum Analysis for Gaucher Disease








































FIG. 4. a, principal component analysis, utilizing Pareto scaling, of the accurate mass/retention time pairs of the depleted serum samples,
pretreatment (red diamonds), post-treatment (black squares), and control serum (blue triangles). b, partial least squares projection to latent
structures analysis, supervised clustering utilizing Pareto scaling, of the absolute amounts (pg/ml) of the serum proteins common to all
conditions. Conditions are: undepleted pretreatment (purple circles), undepleted post-treatment (red diamonds), undepleted control serum
(pink squares), depleted pretreatment (blue triangles), depleted post-treatment (black squares), and depleted control serum (green stars).
treatm., treatment.
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reported to be reproducible and robust.5 Extreme instances
were observed where 80% of non-targeted protein was
removed, e.g. clusterin and complement C1r, or the protein
concentration was not affected, e.g. 1B-glycoprotein, 1-
microglycoprotein, and kininogen. These findings are intrigu-
ing but will vary dependent on the applied depletion technol-
ogy (affinity efficiency and kinetics) and protein-protein
interactions and how well the latter can be minimized.
PCA at the protein level using absolute concentrations also
illustrates the effect of treatment as the cluster for the post-
treatment sample migrates closer to the control, agreeing with
5 Chakraborty, A. B., Berger, S. J., Dorschel, C., Geromanos, S. J.,
Li, G.-Z., and Gebler, J. C. (2006) Is subtractive affinity depletion of
abundant serum proteins useful and reproducible?, Poster 547 pre-
sented at the 54th ASMS Conference on Mass Spectrometry, Seattle,
WA (May 28–June 1, 2006).
FIG. 5. Unweighted average hierarchical clustering with euclidean distance similarity measurement of the 2log absolute concen-
trations (fmol/l) of the triplicate injections of the depleted serum samples by means of euclidean (nearest) distance similarity
measurements. The color legend for the heat map is as follows: lowest abundance, blue; medium abundance, white; highest abundance, red.
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the relative quantification experiment results (Fig. 2). Also here
it can be observed that triplicate injections cluster together
and that PCA is well suited for multivariate analysis of multi-
condition experiments.
A common method for the multivariate analysis of gene
expression or 2D gel sample set visualization is hierarchal
clustering. The determined absolute protein concentrations
by LC-MS can also be applied to this type of analysis. The
2log values of the absolute quantities were used to cluster
injections of the depleted samples. As illustrated by the con-
dition dendrograms displayed on the top of the heat map
visualization (Fig. 5), the triplicate injections for each condition
are closest in origin similarity with the pre- and post-treatment
sample next closest. This is in agreement with the PCA results
at the identification/protein concentration level (Fig. 4). Differ-
ences in expression and concentration can be easily distin-
guished in heat map visualizations. For example, in the selec-
tion (Fig. 5), three proteins are highly abundant in the pre- and
post-treatment sample and not identified in the control, cor-
responding to fibrinogen , , and  chains.
K-means Clustering—The intensities of peptides identified
to a protein can also be clustered based upon their profile by
K-means clustering. This method is used for grouping data
points (peptide precursor intensities) identified to a protein
into a predetermined number of clusters based on their sim-
ilarity. Three example clusters for the depleted samples will be
discussed. The first cluster (Fig. 6a) comprises 60 specific
peptide profiles. This particular cluster highlights the re-
sponse of a group of peptides to treatment. The three left
columns correspond to the triplicate injections of post-treat-
ment, the middle three columns correspond to pretreatment,
and the right three columns correspond to control serum
samples. The profiled peptides can be mapped to their parent
proteins and summarized in detail (see Supplemental Table 3).
10 proteins contributed at least three peptides to the profile,
accounting for 74% of the identified peptides within the clus-
ter. For the second example cluster (Fig. 6b), three proteins
contributed with at least three peptides, accounting for 82%
of the identified profiles. In the last example (Fig. 6c), one
protein contributed to all peptide profiles (100%).
These results demonstrate the possibility of grouping pep-
tides based on their profile change across conditions leading
to the identification of proteins from multiple peptide profiles.
Possibly this can also be used to identify proteins that are
involved in the same biological process or pathway. For in-
stance, of the 10 proteins that contributed to the first profile
cluster, six are part of the complement and coagulation cas-
cades (34), namely complement C3 and C4, complement
factors B and H, kininogen, and plasminogen. The lower
intensity peptides of these proteins clustered together into
two other clusters, which have a profile shape almost identical
to this cluster. Additional proteins were identified within these
clusters that are also part of the complement cascade path-
way, namely complement C1R, C1S, C2, C5, C6, C6, and
C8 and complement factor 1. Hence all proteins identified in
the complement cascade pathway show the same regula-
tion trends (see Supplemental Fig. 1). It has been reported
that Gaucher patients show a low level of coagulation acti-
vation. In a study with 30 patients, parameters of coagula-
tion and fibrinolysis were analyzed pre- and post-treatment
with enzyme replacement therapy (32). Severe abnormali-
ties in the coagulation system were noted, contributing to
the bleeding tendency of Gaucher patients. The reduction in
serum content of the proteins in the coagulation pathway in
this study is consistent with the earlier investigation (32).
The same holds for the observed increase in fibrinogen , ,
and  chain described in the previous hierarchical clustering
section.
The second cluster (Fig. 6b) represents proteins that are
up-regulated in patient pre- and particularly in post-treatment
samples; these are the previously mentioned fibrinolysis pro-
teins. The third cluster (Fig. 6c) represents apolipoprotein A-I,
FIG. 6. K-means clustering examples, Euclidean distance similarity measurement and data centroid-based search cluster initial-
ization, of the intensities of peptides positively identified to a protein for the depleted serum samples, post-treatment (left three
columns), pretreatment (middle three columns) and control serum (right three columns). The maximum number of clusters (K) was
defined as 50. Detailed information in terms of number of identified peptide and proteins for profiles a, b, and c is provided in supplemental
Table 3.
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a protein down-regulated in pre-treatment and only marginally
normalizing upon therapy. Apolipoprotein A-I is a component
of the high density lipoprotein serum content. The high den-
sity lipoprotein in Gaucher patients is extremely low and
known to be poorly normalized following enzyme replacement
therapy (6). The results obtained with the presented label-free
quantitative MS methods are, therefore, again consistent with
biochemical findings. Further investigation of the cluster pro-
files is ongoing to identify potentially new markers of interest
and relationships between the identified proteins.
DISCUSSION
A label-free LC-MS method has been described for the
absolute and relative quantification of Gaucher disease-re-
lated biomarkers and indicators in undepleted and affinity-
depleted serum. Several novel concepts have been presented
including absolute protein concentration measurement in se-
rum, PCA using absolute serum protein concentrations, clus-
tering of peptide profiles to elucidate protein families, and
condition-specific signatures based upon LC-MS data. To our
knowledge these techniques have not been described previ-
ously and are presented here for the first time. The level of
chitotriosidase was estimated by the absolutely determined
amounts identified in depleted patient serum and found to be
in good agreement with the level based on the activity meas-
ured by means of a biochemical assay. This was compared
with serum chitotriosidase levels determined from three fur-
ther type I Gaucher patients of which all showed a significant
overexpression of this protein compared with control serum.
Furthermore clustering approaches have been presented that
allow for data quality assessment when the data are analyzed
at the accurate mass/retention time level. Cluster analyses at
the absolute protein concentration level revealed protein re-
lationships and treatment effects and were confirmed with
biochemical assay data as well. Condition-unique LC-MS
protein signatures were established that allow for the analysis
of a single condition. The absolute concentration LC-MS sig-
natures do not require comparative analysis and are therefore
easily extended to larger scale studies. Lastly peptide inten-
sity clustering was shown for the identification of proteins
involved in either the same complex or biochemical pathway.
12 proteins were identified that are all involved in the com-
plement cascade using this approach, illustrating that they
share similar expected stoichiometry.
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